Plasmid contract manufacturing organization (CMO) VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals focused on developing DNA-based, Neoantigen-targeting personalized cancer immunotherapies, have entered into a long-term master supply agreement. The agreement will leverage VGXI’s experienced management team and decades of plasmid manufacturing proficiency to establish small-scale and rapid turnaround production services ideally suited for the personalized therapy app...